• 1. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 2. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 3. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 4. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 5. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Sulfanylbenzoic acids and derivatives

Benzoic acid, 4-methyl-3-(methylthio)- and Its Synthesis, Bioactivity, and Applications in Pharmaceutical Research

Benzoic acid, 4-methyl-3-(methylthio)- (CAS No. 166811-59-2) is a multifunctional organic compound that has garnered significant attention in the pharmaceutical and biochemical research fields due to its unique structural features and potential therapeutic applications. This compound belongs to the class of substituted benzoic acids, characterized by the presence of a methylthio group at the 3-position and a methyl substituent at the 4-position of the benzene ring. The methylthio group, which consists of a sulfur atom bonded to a methyl group, plays a critical role in modulating the compound's chemical reactivity and biological interactions. Recent studies have highlighted its potential as a scaffold for drug development, particularly in the design of molecules targeting inflammatory pathways and neurodegenerative disorders.

Benzoic acid, 4-methyl-3-(methylthio)- is synthesized through a series of well-defined organic reactions, including electrophilic substitution and sulfide functionalization. One of the most promising synthetic routes involves the methylthio group introduction via a nucleophilic substitution reaction, where a sulfur-containing reagent reacts with the aromatic ring under controlled conditions. This method allows for precise control over the regioselectivity and stereochemistry of the final product. The methyl substituent at the 4-position further enhances the compound's lipophilicity, which may influence its ability to cross biological membranes and interact with target proteins. Researchers have also explored methylthio-functionalized derivatives as potential inhibitors of specific enzymes, such as acetylcholinesterase, which are implicated in neurodegenerative diseases like Alzheimer's.

Recent advances in computational chemistry have provided new insights into the methylthio group's role in modulating the Benzoic acid, 4-methyl-3-(methylthio)- molecule's interactions with biological targets. A 2023 study published in *Journal of Medicinal Chemistry* demonstrated that the methylthio group can act as a hydrogen bond acceptor, enabling the compound to form stable interactions with amino acid residues in protein active sites. This property has been leveraged in the design of small-molecule inhibitors targeting the methylthio-dependent pathways involved in inflammatory responses. The methyl substituent at the 3-position further contributes to the compound's conformational flexibility, allowing it to adopt multiple binding orientations that enhance its selectivity for specific receptors.

Benzoic acid, 4-methyl-3-(methylthio)- has also shown promise in the development of methylthio-based prodrugs for improved drug delivery. Prodrug strategies often involve the incorporation of methylthio groups to mask reactive functionalities, which are then activated in vivo by enzymatic or chemical cleavage. For example, a 2022 study in *Drug Discovery Today* reported that methylthio-modified derivatives of Benzoic acid, 4-methyl-3-(methylthio)- exhibited enhanced solubility and bioavailability compared to their non-modified counterparts. This finding has significant implications for the treatment of diseases requiring systemic drug delivery, such as cancer and autoimmune conditions.

Benzoic acid, 4-methyl-3-(methylthio)- is also being investigated for its potential role in methylthio-dependent signaling pathways. Recent research has linked methylthio groups to the modulation of redox homeostasis and oxidative stress, which are critical factors in the progression of chronic diseases. A 2024 review in *Bioorganic & Medicinal Chemistry* highlighted the methylthio group's ability to act as a sulfhydryl donor, enabling it to participate in disulfide bond formation and protein folding processes. These properties suggest that Benzoic acid, 4-methyl-3-(methylthio)- may serve as a therapeutic agent for conditions involving protein misfolding, such as Parkinson's disease and cystic fibrosis.

The methylthio group's versatility in Benzoic acid, 4-methyl-3-(methylthio)- has also led to its incorporation into hybrid molecules that combine multiple pharmacological activities. For instance, a 2023 study in *ACS Medicinal Chemistry Letters* described the synthesis of methylthio-functionalized compounds that exhibit both anti-inflammatory and antioxidant properties. These dual-action molecules have shown potential in the treatment of inflammatory bowel diseases and other conditions characterized by chronic inflammation and oxidative damage. The methyl substituent at the 4-position further enhances the compound's ability to interact with lipid membranes, which may contribute to its anti-inflammatory effects.

Benzoic acid, 4-methyl-3-(methylthio)- is also being explored as a building block for the development of methylthio-based antiviral agents. A 2022 study in *Antiviral Research* demonstrated that methylthio-derivatives of Benzoic acid, 4-methyl-3-(methylthio)- can inhibit the replication of certain RNA viruses by interfering with their polymerase activity. This finding has sparked interest in the potential use of methylthio-modified compounds as antiviral therapies, particularly for emerging viral pathogens that pose significant public health threats.

Despite its promising applications, the development of Benzoic acid, 4-methyl-3-(methylthio)- as a therapeutic agent requires further optimization to enhance its pharmacokinetic properties and reduce potential side effects. Researchers are currently investigating strategies to improve the compound's metabolic stability and target specificity, such as the incorporation of methylthio-based moieties that can modulate its interaction with cellular receptors. Additionally, the methylthio group's role in Benzoic acid, 4-methyl-3-(methylthio)-'s toxicity profile is being studied to ensure its safety in long-term therapeutic use.

In conclusion, Benzoic acid, 4-methyl-3-(methylthio)- represents a valuable platform for the design of novel therapeutics due to its unique structural features and the versatility of the methylthio group. Its potential applications in pharmaceutical research span a wide range of therapeutic areas, from neurodegenerative diseases to viral infections. Continued exploration of methylthio-based derivatives and their biological activities will likely uncover new opportunities for the development of Benzoic acid, 4-methyl-3-(methylthio)- as a transformative agent in modern medicine.

• 825-99-0(3-(methylsulfanyl)benzoic acid)
• 1527-12-4(2-(Phenylthio)benzoic acid)
• 3724-10-5(2-(Methylthio)benzoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)